Arteriosclerosis Patents (Class 514/824)
  • Patent number: 9023402
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: April 1, 2011
    Date of Patent: May 5, 2015
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 8975230
    Abstract: Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: March 10, 2015
    Assignee: Trustees of Boston University
    Inventors: Kenneth Walsh, Yuichi Oshima, Noriyuki Ouchi
  • Patent number: 8936818
    Abstract: A pomegranate beverage including a pomegranate juice component prepared by crushing and squeezing whole fruits of pomegranate including inner and outer peels and seeds to yield a juice component and an insoluble by-product component, where the juice component separated from the insoluble by-product component to obtain the pomegranate juice component, and an amount of a pomegranate extract component including at least 30 to 3000 ?mols of polyphenols, where the beverage is prepared by a process including re-suspending the insoluble by-product component in an aqueous medium, mixing the re-suspended insoluble by-product component and the aqueous medium, and separating an aqueous extract from the insoluble by-product component to obtain the pomegranate extract component, where the aqueous extract includes polyphenols resulting from the insoluble by-product component.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: January 20, 2015
    Assignee: POM Wonderful, LLC
    Inventors: Michael Aviram, Leslie Dornfeld
  • Patent number: 8791099
    Abstract: Transition metal complexes of amphiphilic/bipolar corroles, optically active isomers or pharmaceutically acceptable salts thereof are useful for prevention of a cardiovascular disease or disorder in a subject susceptible to develop such a cardiovascular disease or disorder.
    Type: Grant
    Filed: August 4, 2008
    Date of Patent: July 29, 2014
    Assignee: Technion Research and Development Foundation Ltd.
    Inventors: Zeev Gross, Michael Aviram, Adi Haber, Bianca Fuhrman, Atif Mahammed, Raymond Coleman
  • Patent number: 8729124
    Abstract: The invention is directed to a method for preventing cerebral damage in patients having symptoms of atherosclerosis of arteries supplying the brain by administering to the patient a therapeutically effective amount of a composition comprising eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA) or a combination thereof.
    Type: Grant
    Filed: November 2, 2004
    Date of Patent: May 20, 2014
    Assignee: Pronova Biopharma Norge AS
    Inventors: Philip Calder, Robert Grimble, Patrick Gallagher, Cliff Shearman
  • Patent number: 8618084
    Abstract: Compositions and methods for inducing the deposition of elastin by administering compositions including a mineralocorticoid, such as, for example, aldosterone and, optionally, a secondary active agent for enhancing or modulating the effect of the mineralocorticoid are described herein.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: December 31, 2013
    Assignees: Human Matrix Sciences, LLC, The Hospital for Sick Children
    Inventors: Aleksander Hinek, Thomas F. Mitts
  • Patent number: 8552069
    Abstract: Disclosed is a composition including camphene as an active ingredient for preventing or treating obesity, dyslipidemia, fatty liver or insulin resistance syndrome. The composition of the present disclosure including camphene as an active ingredient suppresses differentiation of adipocytes, reduces body fat, reduces visceral fat, reduces total cholesterol level, reduces serum triglyceride level and reduces liver tissue triglyceride level, and thus exhibits preventive or therapeutic activity for obesity, hyperlipidemia or fatty liver. Furthermore, the composition of the present disclosure exhibits the effect of improving type 2 diabetes or insulin resistance and related metabolic disease by significantly reducing fasting blood sugar level and blood insulin level.
    Type: Grant
    Filed: December 29, 2009
    Date of Patent: October 8, 2013
    Assignee: Industry-Academic Cooperation Foundation, Yonsei University
    Inventor: Tae Sun Park
  • Patent number: 8530466
    Abstract: Novel methods and compositions for the prevention and treatment of all forms of atherosclerosis with 2,4-pyrimidinediamine compounds are described. Also disclosed is the coating of prosthetic devices, such as stents, with the compounds of the invention for the prevention and/or treatment of restenosis.
    Type: Grant
    Filed: February 20, 2009
    Date of Patent: September 10, 2013
    Assignee: Rigel Pharmaceuticals, Inc.
    Inventors: Esteban Masuda, Jochen Schmitz
  • Patent number: 8415384
    Abstract: Embodiments of the invention are directed to methods of treating reperfusion or resuscitation injury in an individual in need of such treatment, comprising the step of administering to the individual who has had, having, or is at immediate risk of having an ischemic event an amount of a composition comprising a protein kinase A (PKA) activator and a ?1-adrenergic receptor antagonist sufficient to reduce reperfusion injury to an ischemic tissue.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: April 9, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventors: Ming-He Huang, Kenichi Fujise, Barry F. Uretsky
  • Patent number: 8383650
    Abstract: The present invention relates to a compound of the formula I wherein R1, R2, R3, R4 and R5 are as defined in the specification, for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations a compound of that class; a method of treatment comprising administering a compound of that class and a method for its manufacture.
    Type: Grant
    Filed: June 25, 2008
    Date of Patent: February 26, 2013
    Assignee: Novartis AG
    Inventors: Fumiaki Yokokawa, Takeru Ehara, Shimpei Kawakami, Osamu Irie, Masaki Suzuki, Yuko Hitomi, Atsushi Toyao
  • Patent number: 8377916
    Abstract: The invention relates to compounds of formula (I): wherein R is ethyl, propyl or allyl, and pharmaceutically acceptable salts, solvates or amino acid conjugates thereof. The compounds of formula (I) are useful as FXR agonists.
    Type: Grant
    Filed: November 3, 2011
    Date of Patent: February 19, 2013
    Assignee: Intercept Pharmaceuticals, Inc.
    Inventor: Roberto Pellicciari
  • Patent number: 8343549
    Abstract: A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crude Dunaliella powder, optionally together with an activator of nuclear receptors.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: January 1, 2013
    Assignees: Nikken Sohonsha Corporation, Tel Hashomer Medical Research Infrastructure and Services Ltd.
    Inventors: Aviv Shaish, Dror Harats
  • Patent number: 8329650
    Abstract: Described herein are methods and compositions related to the discovery that the Follistatin-like 1 protein (Fstl-1) has metabolic and cardioprotective effects in vivo. Fstl-1 and portions and derivatives or variants thereof can be used to treat or prevent metabolic diseases or disorders and to treat or prevent cardiac damage caused by interrupted cardiac muscle blood supply.
    Type: Grant
    Filed: October 20, 2008
    Date of Patent: December 11, 2012
    Assignee: Trustees of Boston University
    Inventors: Kenneth Walsh, Yuichi Oshima, Noriyuki Ouchi
  • Patent number: 8324152
    Abstract: The present invention concern a composition or a patch adapted for the prophylactic or therapeutic treatment by continuous subcutaneous administration of a subject suffering from atherosclerosis, comprising an effective amount of at least one epitope derived from a protein present in the atherosclerotic plaque, whereby administration of said at least one epitope to said subject induces a specific regulatory immune response, preferably a Treg response.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: December 4, 2012
    Assignee: Institute National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Alain Tedgui, Ziad Mallat
  • Patent number: 8158153
    Abstract: Nanoparticulate bisphosphonate compositions, having an effective average particle size of less than 2000 nm, are described. The compositions are useful in treating bone resorption in a mammal.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: April 17, 2012
    Assignee: Alkermes Pharma Ireland Limited
    Inventors: Gary G. Liversidge, Scott Jenkins
  • Patent number: 8147876
    Abstract: An object of the present invention is to provide a medical agent that has an excellent effect on the diseases resulting from one of inflammation and remodeling and that can prevent or treat them in response to various mechanisms of onset and development of the diseases. Thus, the present invention relates to a medical agent for preventing or treating diseases resulting from one of inflammation and remodeling in blood vessel, including nanobubbles.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: April 3, 2012
    Assignees: National University Corporation Tokyo Medical and Dental University, REO Laboratory, Co., Ltd.
    Inventors: Yukihiro Hojo, Kaneo Chiba, Yoshihiro Mano
  • Patent number: 8053449
    Abstract: Various methods of administering medication(s) that inhibit the nonenzymatic formation of glycation and dehydration condensation complexes known as advanced glycation end-products (AGEs) or modulate the advanced glycation end-product receptor (RAGE) are provided. Also, a medication releasing medical devices, wherein at least a portion of the medical device releasably includes at least one of these medication(s) are provided.
    Type: Grant
    Filed: October 2, 2006
    Date of Patent: November 8, 2011
    Assignee: Cell Viable Corporation
    Inventor: Jill D. Fabricant
  • Patent number: 7964220
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: June 14, 2006
    Date of Patent: June 21, 2011
    Assignee: ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda.
    Inventors: Werner E. Haas, Carlos C. Romao, Beatriz Royo, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7939287
    Abstract: Provided herein are compositions and methods for identifying individuals at risk for developing coronary artery disease (CAD).
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: May 10, 2011
    Assignee: The Regents of the University of California
    Inventors: Sotirios Tsimikas, Joseph Witztum
  • Patent number: 7883699
    Abstract: The invention provides methods to for treating a an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.
    Type: Grant
    Filed: August 22, 2008
    Date of Patent: February 8, 2011
    Assignee: Proteon Therapeutics, Inc.
    Inventor: F. Nicholas Franano
  • Patent number: 7754715
    Abstract: The present invention, which is applicable in the pharmaceutical industry, relates to the use of molsidomine or one of its pharmaceutically acceptable salts, especially in the form of a sustained-release solid oral composition effective over 24 hours, for the manufacture of a drug for preventing or reducing the development of atherosclerosis.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: July 13, 2010
    Assignee: Therabel Pharmaceuticals Limited
    Inventor: Jozsef-Michel Geczy
  • Patent number: 7708990
    Abstract: The object of the present invention is to provide a composition maintaining a blood coenzyme Q concentration at a high level in blood for a prolonged period of time, in order to surely attain an effect of coenzyme Q, which can be expected to manifest a superior effect in maintaining health in humans and animals. By using a composition which comprises a coenzyme Q being a mixture of a reduced coenzyme Q and an oxidized coenzyme Q with the proportion of the reduced coenzyme Q to the whole coenzyme Q of more than 95% by weight, the present invention can attain a high maximum blood concentration of a coenzyme Q as well as long maintenance of high concentration of coenzyme Q in blood for a prolonged period of time, and the area under the blood concentration curve (AUC) can be expanded.
    Type: Grant
    Filed: March 22, 2005
    Date of Patent: May 4, 2010
    Assignee: Kaneka Corporation
    Inventors: Kenji Fujii, Taizo Kawabe, Hiroshi Kubo
  • Patent number: 7666900
    Abstract: To provide a pharmaceutically effective prophylactic/preventive agent for low-HDL cholesterolemia, focusing on an HDL-generating mechanism. The ABCA1 stabilizer of the present invention contains a bisphenol-type compound selected form probucol spiroquinone, probucol diphenoquinone, and probucol bisphenol as an effective ingredient. The ABCA1 stabilizer can continuously and stably express ABCA1 by a mechanism quite different from that of conventional processes, and thus is useful as prophylactic/preventive agent for low-HDL cholesterolemia or arteriosclerosis.
    Type: Grant
    Filed: December 22, 2004
    Date of Patent: February 23, 2010
    Assignee: Hykes Laboratories LLC
    Inventors: Shinji Yokoyama, Maki Tsujita, Reijiro Arakawa, Tomoji Aotsuka
  • Patent number: 7652143
    Abstract: The present invention relates to a novel compound of the formula I: and/or all stereoisomeric forms of the compound of the formula I and/or mixtures of these forms in any ratio, and/or a physiologically tolerated salt of the compound of the formula I, in which R1 to R5 and V1, V2 have the meanings stated in the claims and specification. The inventive compounds are suitable as inhibitors of metalloproteases, especially of ADAMTS proteases and TNF-? converting enzyme (TACE), and for the treatment of disorders such as but not limited to osteoarthrosis and rheumatoid arthritis.
    Type: Grant
    Filed: June 15, 2007
    Date of Patent: January 26, 2010
    Assignee: sanofi-aventis Deutschland GmbH
    Inventors: Andreas Lindenschmidt, Holger Wagner, Jochen Beninga, Sven Grueneberg, Klaus-ulrich Weithmann
  • Patent number: 7553482
    Abstract: The invention relates to the use of an adsorption material which has been modified with polynuclear metal oxide hydroxides for influencing the calcium level and, in particular, for treating or/and preventing atherosclerotic vascular diseases or/and disturbances of bone metabolism.
    Type: Grant
    Filed: June 12, 2002
    Date of Patent: June 30, 2009
    Assignee: Novartis International Pharmaceutical Ltd
    Inventors: Dietrich Seidel, Karl-Siegfried Boos
  • Patent number: 7534438
    Abstract: Disclosed are compositions and methods for decreasing the viscosity and/or cohesiveness of and/or increasing the liquefaction of excessively or abnormally viscous or cohesive mucus or sputum. The composition contains a protein or peptide containing a thioredoxin active-site in reduced state and optionally further contains a reducing system.
    Type: Grant
    Filed: March 2, 2007
    Date of Patent: May 19, 2009
    Assignee: National Jewish Health
    Inventor: Carl W. White
  • Patent number: 7416743
    Abstract: A polyherbal preparation for the prevention of atherosclerosis and hyperlipidemia comprising a mixture of Commiphora mukul, Boswellia serrata, Semecarpus anacardium Strychnox nux vomica, Terminalia arjuna and Shankha Bhasma.
    Type: Grant
    Filed: December 26, 2003
    Date of Patent: August 26, 2008
    Assignees: Department of Biotechnology, Banaras Hindu University
    Inventor: Yamini Bhushan Tripathi
  • Patent number: 7361684
    Abstract: Transgenic animals that do not express functional SR-BI and ApoE develop severe atherosclerosis, by age four weeks in transgenic mice. Moreover, these animals exhibit progressive heart dysfunction by as early as age four weeks, and die by age nine weeks. This animal model has now been demonstrated to be useful as a screen for compounds which alleviate the symptoms of atherosclerosis and heart disease. Animals (Apo E?/? SR-BI+/?) were fed PROBUCOL beginning at the time of mating. Offspring are weaned at three weeks and fed PROBUCOL. In contrast to animals (Apo E?/? SR-BI?/?) not fed PROBUCOL, 50% of whom are dead at six weeks, all animals (Apo E?/? SR-BI?/?) on PROBUCOL have a normal phenotype (MRI of heart function, ECG, echocardiogram, histology) at six weeks. At seven to eight months, there is evidence of atherosclerosis and some myocardial infarction. This demonstrates that the compound has a preventative action. Animals who are taken off of the PROBUCOL all die within ten to twelve weeks.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: April 22, 2008
    Assignee: Massachusetts Institute of Technology
    Inventors: Monty Krieger, Anne Braun, Helena E. Miettinen
  • Patent number: 7179791
    Abstract: Patients needing NO donor therapy or inhibition of pathologically proliferating cells or increased NO bioactivity are treated with a therapeutically effective amount of an inhibitor of glutathione-dependent formaldehyde dehydrogenase.
    Type: Grant
    Filed: January 11, 2001
    Date of Patent: February 20, 2007
    Assignee: Duke University
    Inventors: Jonathan S. Stamler, Limin Liu, Alfred Hausladen, Raphael Nudelman
  • Patent number: 7153877
    Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.
    Type: Grant
    Filed: December 9, 2004
    Date of Patent: December 26, 2006
    Assignee: Interhealth Nutraceuticals Incorporated
    Inventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
  • Patent number: 7141558
    Abstract: Biologically active 19-nor vitamin D analogs substituted at C-2 in the A-ring with an ethylidene or an ethyl group. These compounds have preferential activity on mobilizing calcium from bone and either high or normal intestinal calcium transport activity which allows their in vivo administration for the treatment of metabolic bone diseases where bone loss is a major concern. These compounds are also characterized by high cell differentiation activity.
    Type: Grant
    Filed: July 28, 2005
    Date of Patent: November 28, 2006
    Assignee: Wiscousin Alumni Research Foundation
    Inventors: Hector F. DeLuca, Rafal R. Sicinski
  • Patent number: 7125547
    Abstract: The present invention relates to a method for removing bile acids from a patient and certain polymers of use in the method. The method comprises the step of administering to the patient a therapeutically effective amount of a polymer composition which includes a a poly(diallylamine) polymer which is substituted with hydrophobic groups. The hydrophobic groups can be a substituted or unsubstituted, straight chain or branched C3–C24-alkyl group, an aralkyl group or an aryl group.
    Type: Grant
    Filed: August 25, 2003
    Date of Patent: October 24, 2006
    Assignee: Genzyme Corporation
    Inventors: Stephen Randall Holmes-Farley, Pradeep K. Dhal, John S. Petersen
  • Patent number: 7119110
    Abstract: A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bound chromium that prevents or reduces the symptoms. Compositions incorporating niacin-bound chromium and additional compounds also are disclosed that are particularly effective in synergistically preventing or reducing these symptoms.
    Type: Grant
    Filed: October 4, 2002
    Date of Patent: October 10, 2006
    Assignee: Interhealth Nutraceuticals Incorporated
    Inventors: Debasis Bagchi, Harry G. Preuss, Shil C. Kothari
  • Patent number: 7112338
    Abstract: Angiogenic endothelial cells are selectively targeted with lipid/DNA complexes or cationic liposomes containing a substance which affects the targeted cells by inhibiting or promoting their growth. A site of angiogenesis can be precisely located by administering cationic liposomes containing a detectable label. The complexes may comprise nucleotide constructs which are comprised of promoters which are selectively and exclusively activated in the environment of an angiogenic endothelial cell.
    Type: Grant
    Filed: May 28, 2002
    Date of Patent: September 26, 2006
    Assignee: The Regents of the University of California
    Inventors: Donald M. McDonald, John W. McLean, O. Gavin Thurston
  • Patent number: 7109187
    Abstract: The application discloses methods of treating mammalian diseases characterized by abnormal cell mitosis by administering estradiol derivatives including those comprising colchicine or combretastatin A-4 structural motifs of the general formulae found below in a dosage sufficient to inhibit cell mitosis. The application discloses novel compounds used in the methods.
    Type: Grant
    Filed: February 12, 2001
    Date of Patent: September 19, 2006
    Assignee: The Children's Medical Center Corporation
    Inventors: Robert John D'Amato, Moses Judah Folkman
  • Patent number: 7101570
    Abstract: The present invention provides compositions and methods for treating atherosclerosis. The compositions comprise unilamellar liposomes having an average diameter of 100-150 nanometers. Methods for treating atherosclerosis employing the compositions of the present invention are also provided.
    Type: Grant
    Filed: November 5, 2001
    Date of Patent: September 5, 2006
    Assignee: The University of British Columbia
    Inventors: Michael J. Hope, Wendi Rodrigueza
  • Patent number: 7101838
    Abstract: The present invention provides for a method to prevent accelerated atherosclerosis in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent accelerated atherosclerosis in the subject. The present invention also provides for a method to prevent a macrovessel disease in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to prevent macrovessel disease in the subject.
    Type: Grant
    Filed: August 5, 1997
    Date of Patent: September 5, 2006
    Assignee: The Trustees of Columbia University in the City of New York
    Inventors: David Stern, Ann Marie Schmidt
  • Patent number: 7087223
    Abstract: Provided in a phosphate ion adsorbent containing a weakly basic anion exchange resin as an active ingredient which aims at providing preventives and/or remedies for hyperphosphatemia having a high selectivity for the adsorption of phosphate ion and showing an effect of lowering blood phosphorus level and another effect of suppressing phosphorus excretion into the urine.
    Type: Grant
    Filed: November 9, 2004
    Date of Patent: August 8, 2006
    Assignee: Hisamitsu Pharmaceutical Co., Inc.
    Inventors: Takeshi Goto, Kazuhisa Yoshitake, Hiroshi Sorimachi, Kazuteru Moriyama
  • Patent number: 7084109
    Abstract: This invention provides novel compounds which prevent or block a FVIIa mediated or associated process or event such as the catalytic conversion of FX to FXa, FVII to FVIIa or FIX to FIXa. In particular aspects, the compounds of the invention bind Factor VIIa (FVIIa), its zymogen Factor VII (FVII) and/or block the association of FVII or FVIIa with a peptide compound of the present invention. The invention also provides pharmaceutical compositions comprising the novel compounds as well as their use in diagnostic, therapeutic, and prophylactic methods.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: August 1, 2006
    Assignee: Genentech, Inc.
    Inventors: Mark S. Dennis, Charles Eigenbrot, Robert A. Lazarus
  • Patent number: 7078396
    Abstract: A method of treating a disorder related to a high cholesterol concentration, comprising administering to a subject in need thereof a compound of formula (I): Also disclosed are methods, kits, combinations, and compositions for treating a disorder in a subject where an activator of liver X alpha is indicated, such as in, for example, treating a high cholesterol disease.
    Type: Grant
    Filed: November 8, 2002
    Date of Patent: July 18, 2006
    Assignee: ARCH Development Corporation
    Inventors: Ching Song, Shutsung Liao
  • Patent number: 7078411
    Abstract: A method for controlling cholesterol metabolism in a host, a screening assay for agents that can control cholesterol metabolism, and the agents that may be identified are practiced and determined in relation to the expression of PLTP in HepG2 cells and a clone from these cells, designated HepG2/PLTPpLuc. Particular agents that are covered comprise camptothecin, topotecan, derivatives thereof, metabolic byproducts thereof and small molecule mimics thereof.
    Type: Grant
    Filed: May 15, 2002
    Date of Patent: July 18, 2006
    Assignee: UMDNJ (Univ of Medicine & Dentist. of NJ)
    Inventor: Khew-Voon Chin
  • Patent number: 7022722
    Abstract: The subject invention provides pharmaceutical compounds useful in the treatment of Type II diabetes. These compounds are advantageous because they are readily metabolized by the metabolic drug detoxification systems. Particularly, thiazolidinedione analogs that have been designed to include esters within the structure of the compounds are provided. This invention is also drawn to methods of treating disorders, such as diabetes, comprising the administration of therapeutically effective compositions comprising compounds that have been designed to be metabolized by serum or intracellular hydrolases and esterases. Pharmaceutical compositions of the ester-containing thiazolidinedione analogs are also taught.
    Type: Grant
    Filed: January 16, 2004
    Date of Patent: April 4, 2006
    Assignee: ARYx Therapeutics, Inc.
    Inventors: Pascal Druzgala, Peter G. Milner, Jurg R. Pfister
  • Patent number: 7011854
    Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: March 14, 2006
    Assignee: Alfama-Investigacao e Desenvolvimento de Produtos Farmaceuticos Lda
    Inventors: Werner Haas, Carlos Romao, Beatriz Roya, Ana Cristina Fernandes, Isabel Goncalves
  • Patent number: 7008645
    Abstract: A method of inhibiting the activity or production of cytokines or growth factors associated with vascular restenosis, by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.
    Type: Grant
    Filed: May 30, 2002
    Date of Patent: March 7, 2006
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Gershon Golomb, Haim Danenberg
  • Patent number: 6989165
    Abstract: The present invention relates to a synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of plant Gentiana kurroo of concentration ranging between 2–5 wt. %, Murraya koenigii of concentration ranging between 8–15 wt %, Allium sativum of concentration ranging between 2–4 wt %, Zingiber officinalis of concentration ranging between 2–5 wt %, Amorphophallus campanulatus of concentration ranging between 1–10%, and pharmaceutically acceptable additive(s); a process for the preparation of the said synergistic pharmaceutical composition; and also, a use of the said composition for treating hyperlipidemia, atherosclerosis, and obesity.
    Type: Grant
    Filed: March 31, 2004
    Date of Patent: January 24, 2006
    Assignee: Council of Scientific and Industrial Research
    Inventors: Palpu Pushpangadan, Shanta Mehrotra, Chandana Venkateswara Rao, Sanjeev Kumar Ojha, Govindarajan Raghavan, Guntupalli Madan Mohana Rao, Sreedevi Padmavathi
  • Patent number: 6984400
    Abstract: A method of treating or preventing restenosis by administering to an individual an effective amount of an active ingredient comprising a bisphosphonate particle or a bisphosphonate particulate. The bisphosphonate may be encapsulated, embedded or adsorbed within the particle, dispersed uniformly in the polymer matrix, adsorbed on the particle surface, or in combination of any of these forms. The particles include liposomes or inert polymeric particles, such as microcapsules, nanocapsules, nanoparticles, nanospheres, or microparticles. The particulates include any suspended or dispersed form of the bisphosphonate which is not encapsulated, entrapped, or adsorbed within a polymeric particle. The particulates include suspended or dispersed colloids, aggregates, flocculates, insoluble salts and insoluble complexes of the active ingredient.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: January 10, 2006
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Gershon Golomb, Haim Danenberg
  • Patent number: RE39150
    Abstract: A composition including 2-hexyl cyanoacrylate and goal is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.
    Type: Grant
    Filed: March 30, 2001
    Date of Patent: June 27, 2006
    Assignee: Prohold Technologies, Inc.
    Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
  • Patent number: RE39734
    Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.
    Type: Grant
    Filed: July 13, 2005
    Date of Patent: July 17, 2007
    Inventor: Albert Crum
  • Patent number: RE42377
    Abstract: A composition including 2-hexyl cyanoacrylate and gold is useful in treating arteriovenous malformations (AVMs) and other body lumens to be blocked.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: May 17, 2011
    Assignees: Stryker Corporation, Stryker NV Operations Limited
    Inventors: Robert E. Krall, Charles W. Kerber, Kimberly Knox
  • Patent number: RE42645
    Abstract: Nutritional or therapeutic compositions containing glutamic acid, cystine, glycine and a selenium precursor and methods for their utilization to increase glutathione synthesis and thereby enhance the immune system are described.
    Type: Grant
    Filed: March 9, 2006
    Date of Patent: August 23, 2011
    Inventor: Albert Crum